Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

Nature Clinical Practice Oncology

Volumn 3, Issue 1, 2006, Pages 12-13

  Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Chemotherapy; HER2; Survival; Trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

AXILLARY LYMPH NODE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HAZARD ASSESSMENT; HEART DEATH; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MASTECTOMY; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SHORT SURVEY; SURVIVAL RATE; SURVIVAL TIME;

EID: 30944443605     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0401     Document Type: Short Survey

References (4)

1. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
2. Marty M et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23: 4265-4274
3. Piccart-Gebhart MJ et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672
4. Seidman A et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221